相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Synthesis, Aromatase Inhibitory, Antiproliferative and Molecular Modeling Studies of Functionally Diverse D-Ring Pregnenolone Pyrazoles
Abid H. Banday et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2021)
Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management
Tara Hyder et al.
FRONTIERS IN ENDOCRINOLOGY (2021)
Design and Synthesis of Novel Breast Cancer Therapeutic Drug Candidates Based upon the Hydrophobic Feedback Approach of Antiestrogens
Kiminori Ohta et al.
MOLECULES (2019)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Estrogen alpha receptor antagonists for the treatment of breast cancer: a review
Deepika Sharma et al.
CHEMISTRY CENTRAL JOURNAL (2018)
Direct and Systemic Administration of a CNS-Permeant Tamoxifen Analog Reduces Amphetamine-Induced Dopamine Release and Reinforcing Effects
Colleen Carpenter et al.
NEUROPSYCHOPHARMACOLOGY (2017)
Design and synthesis of novel flexible ester-containing analogs of tamoxifen and their evaluation as anticancer agents
Nehal H. Elghazawy et al.
FUTURE MEDICINAL CHEMISTRY (2016)
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study
Matthew J. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial
Jack Cuzick et al.
LANCET ONCOLOGY (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy
Deirdre P. Cronin-Fenton et al.
FUTURE ONCOLOGY (2014)
Investigation of aromatase inhibitory activity of metal complexes of β-hydroxyquinoline and uracil derivatives
Veda Prachayasittikul et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2014)
Design, synthesis and biological evaluation of novel triaryl (Z)-olefins as tamoxifen analogues
Khaled R. A. Abdellatif et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Synthesis of Mixed (E,Z)-, (E)-, and (Z)-Norendoxifen with Dual Aromatase Inhibitory and Estrogen Receptor Modulatory Activities
Wei Lv et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
Christina Davies et al.
LANCET (2013)
The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents
Wenjie Jessie Lu et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
R. C. Coombes et al.
LANCET (2007)
Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer
V. Craig Jordan et al.
STEROIDS (2007)
Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study
B Fisher et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Aromatase inhibitors in the treatment of breast cancer
RW Brueggemeier et al.
ENDOCRINE REVIEWS (2005)
Role of aromatase inhibitors in the treatment of breast cancer
TK Choueiri et al.
CLINICAL THERAPEUTICS (2004)
Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): Is a clinical benefit still achievable?
P Carlini et al.
ANNALS OF ONCOLOGY (2001)
A high-throughput screen to identify inhibitors of aromatase (CYP19)
DM Stresser et al.
ANALYTICAL BIOCHEMISTRY (2000)
分享论文
